TRDA Stock Analysis: Buy, Sell, or Hold?
TRDA - Entrada Therapeutics, Inc. Common Stock
$6.85
-9.18 (-57.27%)
▼
5d:
-49.26%
30d:
-52.16%
90d:
-31.98%
WAIT
LOW Confidence
Analysis Updated: May 7, 2026 12:00 AM ET
Earnings: May 14, 2026
5d
Get Alerted When TRDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called TRDA this week
0% bullish • 1 bearish
0% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TRDA is down 49.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TRDA is down 49.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TRDA is currently trading at $6.85, which is considered oversold relative to its 30-day fair value range of $11.85 to $15.03.
Technical Outlook: Technically, TRDA is in a uptrend. Immediate support is located at $5.73, while resistance sits at $16.45. Short-term momentum is weak, with the stock down 57.3% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $21.40 (+212.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TRDA is in a uptrend. Immediate support is located at $5.73, while resistance sits at $16.45. Short-term momentum is weak, with the stock down 57.3% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $21.40 (+212.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$11.85 -
$15.03
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-57.3%)
- BULLISH: Trading 212.4% below Wall St target ($21.40)
- WARNING: Recommendation downgraded due to -49.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$11.85 -
$15.03
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$5.73
Resistance Level
$16.45
Current Trend
Uptrend
Technical data as of
May 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.99
Wall Street Target
$21.40
(+212.4%)
Revenue Growth (YoY)
-96.5%
Share & Embed Analysis
Last updated: May 08, 2026 7:12 AM ET
Data refreshes hourly during market hours. Next update: 8:12 AM
Data refreshes hourly during market hours. Next update: 8:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TRDA showing a specific setup today?
Insider Activity (6 Months)
3
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Kory James Wentworth
SELL
2500 shares
2026-04-01
Kory James Wentworth
SELL
11388 shares
2026-03-10
Nathan J Dowden
SELL
11894 shares
2026-03-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$90 | 56 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$93 | 67 BUY |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 57 HOLD |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$174 | 63 BUY |
|
ATYR
aTyr Pharma, Inc. |
STRONG BUY
11 analysts |
$4 | 66 BUY |